Last reviewed · How we verify
Warfarin Dosing
At a glance
| Generic name | Warfarin Dosing |
|---|---|
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rivaroxaban in Idiopathic Membranous Nephropathy (PHASE4)
- Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin (PHASE2)
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement (PHASE4)
- Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
- A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis (PHASE1)
- Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients (PHASE4)
- Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease (PHASE4)
- Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Warfarin Dosing CI brief — competitive landscape report
- Warfarin Dosing updates RSS · CI watch RSS
- University of Florida portfolio CI